What Red Arrow Therapeutics does

Red Arrow Therapeutics is a preclinical-stage biotechnology company developing a proprietary pH-responsive nanopolymer drug delivery platform for biologic payloads. The platform encapsulates biologics — including cytokines, peptides, and antibodies (cationic to anionic proteins) — into micelles that remain inert in circulation and release their payload in response to the acidic tumor microenvironment, enabling on-target, on-tumor delivery with reduced off-target toxicity. The lead pipeline asset is a nanopolymer formulation of the pro-inflammatory cytokine IL-12 for solid tumors, positioned as a combination therapy with checkpoint inhibitors for the roughly 80% of solid tumor patients who do not respond to current immunotherapy. Additional polymer-drug conjugate programs are in discovery.

The company was founded in August 2021 as a spin-off from Prof. Horacio Cabral's laboratory at the University of Tokyo, co-founded by Cabral and Takuya Miyazaki, PhD. It has since relocated its corporate headquarters to Cambridge, Massachusetts while maintaining wet-lab operations in Tokyo, and appointed Philipp Steiner, PhD as Chief Scientific Officer in March 2026. Capitalization totals approximately $5.5–7M in seed equity from a Japanese university-affiliated VC syndicate (UTEC, BNV, KII, OUVC), supplemented by up to ~$47.4M in potential non-dilutive Japanese government funding (AMED Drug Discovery Venture Ecosystem Enhancement Program and NEDO STS).

Red Arrow is pre-revenue with no commercial products and no disclosed pricing. Its intended business model is eventual licensing, co-development partnerships, or acquisition by larger pharmaceutical companies for clinical development and commercialization of its pipeline assets. The team is small (fewer than 10 research staff per the company's job posting), with no commercial sales organization, and its current visibility derives from accelerator participation (UC Berkeley SkyDeck, MassChallenge) and Japanese government grant awards rather than commercial traction.

Name

Red Arrow Therapeutics

Legal name

Red Arrow Therapeutics, Inc.

Website

https://redarrowtx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Red Arrow Therapeutics is a preclinical biotech developing a proprietary pH-responsive nanopolymer platform to deliver cytokines and other biologics to solid tumors, with an IL-12 lead program aimed at the 80% of solid tumor patients who do not respond to checkpoint inhibitors.

Ownership category

akta.pro rank

Product category

Oncology Nanomedicine / Drug Delivery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

akta.pro secondary industries

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Nanomedicine drug delivery
• Polymer drug conjugates
• Cancer immunotherapy platform
• Biologic encapsulation technology
• Cytokine delivery oncology

Headquarters

HQ city

Minato

HQ country

Japan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Pharmaceutical Development: Pre-revenue company developing nanomedicine drug delivery platform for cancer treatment. Revenue model would eventually come from licensing, co-development partnerships, or eventual product sales through pharmaceutical partnerships. Currently in preclinical development stage with research funded by grants.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Red Arrow Therapeutics develops a proprietary pH-responsive nanopolymer drug-delivery platform that encapsulates and releases biologics (including cytokines, small peptides, full-chain antibodies, and cationic/anionic proteins) specifically at tumor microenvironments. Its first pipeline asset delivers pro-inflammatory cytokine IL-12 for solid tumors and is in preclinical development, with additional polymer-drug conjugate cancer drugs in discovery.

Product overview

Red Arrow Therapeutics operates a single integrated platform business model centered on its proprietary Nanopolymer Drug-Delivery System. The core platform enables pH-responsive encapsulation and release of biologic payloads, particularly cytokines for cancer immunotherapy. The first pipeline product is IL-12 loaded nanopolymer micelles for solid tumor treatment, currently in preclinical stage, with additional polymer-drug conjugate cancer drugs in discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• IL-12 Loaded Nanopolymer Micelles Red Arrow's lead pipeline product: a polymer-drug conjugate that systemically delivers pro-inflammatory cytokine IL-12 via nanopolymer micelles to the solid tumor microenvironment, where the cytokine is released to recruit immune cells and induce cancer cell death. Intended for combination therapy with checkpoint inhibitors for solid tumor patients. Currently in preclinical stage.
• Polymer-Drug Conjugate Cancer Drugs (Pipeline) Pipeline of polymer-drug conjugate cancer drugs developed using Red Arrow's proprietary nanopolymer platform for specific on-target on-tumor delivery and reduced on-target off-tumor toxicity. Follow-up pipeline efforts are currently in discovery phase.

Quantifiable outcome

• Cytokine-loaded nanopolymer micelles can target the 80% of solid tumor patients who don't respond to checkpoint inhibitors

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• MassChallengecoreStrategic or Co-development Partner · 1 June 2023Accepted into U.S. Early Stage Growth Cohort program - prestigious startup accelerator focused on early stage companies.
• UC Berkeley SkyDeckcoreStrategic or Co-development Partner · 1 November 2022Selected to join SkyDeck Accelerator Cohort Program with 1.5% acceptance rate worldwide. Dr. Takuya Miyazaki presented at Demo Day Berkeley SKYDECK in April 2023. Previous investment from SkyDeck included in total funding.
• University of TokyocoreStrategic or Co-development PartnerSpin-out from University of Tokyo's Cabral Lab in 2021. Laboratory remains closely associated with the University of Tokyo. Technology developed by Prof. Dr. Horacio Cabral from University of Tokyo.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Selecta Biosciences: Developed synthetic nanoparticle immunotherapies including tolerogenic and immunogenic vaccines, with overlapping focus on programming immune responses using nanoparticle carriers.
• Codiak BioSciences: Developed engineered exosome-based platforms for delivery of biologics including cytokines, the closest mechanistic analogue to Red Arrow's biologic-loaded nanocarrier approach.
• Nanobiotix: Clinical-stage nanomedicine company developing nanoparticle-based cancer therapeutics. Directly comparable as a nanoparticle-platform oncology company, though at a more advanced clinical stage.
• NanoCarrier Co., Ltd. Japanese specialty pharmaceutical company developing micellar nanoparticle drug delivery systems for cancer and other diseases. Closest geographic and technical peer in the Japanese nanomedicine ecosystem.
• Merrimack Pharmaceuticals: Developed nanoliposomal oncology therapeutics (e.g., Onivyde) and built a pipeline around nanoparticle-encapsulated biologics for solid tumors, a comparable biologic-delivery strategy.
• BIND Therapeutics: Pioneered targeted polymeric nanoparticle drug delivery for oncology, including programs delivering cytotoxics and other biologics. Closely aligned platform approach despite corporate restructuring.
• CytImmune Sciences: Developed tumor-targeted gold nanoparticle delivery of TNF and other cytokines to solid tumors, directly comparable in payload (cytokines) and tumor-targeting mechanism.

Emerging players

• Acuitas Therapeutics: Develops lipid nanoparticle (LNP) delivery technology used across nucleic-acid and biologic therapeutics, including for partners in oncology. Comparable as a delivery-platform peer at a more commercial stage.
• PsiOxus Therapeutics: Developed tumor-targeted immunotherapies including cytokine-armed oncolytic viruses, a comparable strategy of localizing potent immunomodulators to the tumor microenvironment.

Broad incumbents

• Arcturus Therapeutics: Clinical-stage biotech using lipid nanoparticle delivery platforms for nucleic-acid and protein-based therapeutics, with broader pipeline and manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/RedArrowTX
• LinkedInlinkedin.com/company/red-arrow-tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Red Arrow Therapeutics